Earnings Summary

Brooklyn ImmunoTherapeutics Inc’s net profit jumped 7.04% since last year same period to $-9.38Mn in the Q2 2022. On a quarterly growth basis, Brooklyn ImmunoTherapeutics Inc has generated -10.67% fall in its net profits since last 3-months.

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a -16.67% fall from last quarter’s estimates.

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Brooklyn ImmunoTherapeutics Inc’s earning per share (EPS) jumped 29.17% since last year same period to -0.17 in the Q2 2022. This indicates that the Brooklyn ImmunoTherapeutics Inc has generated 29.17% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Brooklyn ImmunoTherapeutics Inc’s return on assets (ROA) stands at -0.35.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Brooklyn ImmunoTherapeutics Inc’s return on equity (ROE) stands at -4.27.